What is Deepcure?
Deepcure is a pioneering biotechnology firm operating at the forefront of drug development. The company distinguishes itself through its proprietary AI-driven drug discovery platform, complemented by an automated robotic laboratory. This integrated approach aims to accelerate the identification and development of novel therapeutics, addressing unmet medical needs within the pharmaceutical landscape. The company's focus on advanced technology positions it as a key player in the evolving biotech sector.
How much funding has Deepcure raised?
Deepcure has raised a total of $104M across 2 funding rounds:
Series A
$40M
Series A
$64M
Series A (2021): $40M with participation from TLV Partners, The Morningside Group, Benon Group, and Sapir Venture Partners
Series A (2024): $64M led by The Morningside Group, IAG Capital Partners, Benon Group, and Sapir Venture Partners
Key Investors in Deepcure
TLV Partners
TLV Partners is an Israeli venture capital firm that invests in early-stage startups, collaborating with innovative entrepreneurs to create category-defining companies. With over $1 billion under management, the firm focuses on exceptional teams that are poised to shape the future across various sectors, including AI, healthcare, and application security.
The Morningside Group
Morningside Group was founded in 1986, by the Chan family of Hong Kong, to make private equity and venture capital investments. The group is managed by investment professionals who are entrepreneurial, have deep industry knowledge, and are effective in the local environment in which they operate.
IAG Capital Partners
IAG Capital Partners is a venture capital firm that specializes in leading investment rounds from seed to Series C. The firm operates from offices in Charleston, SC, and London, UK. IAG focuses on providing financial support to innovative companies at various stages of their development.
What's next for Deepcure?
The recent major strategic investment signifies a critical growth phase for Deepcure. This capital infusion is expected to fuel the expansion of its research and development capabilities, potentially enabling the company to accelerate its pipeline of drug candidates through preclinical and clinical stages. The backing from strategic investors suggests confidence in Deepcure's technological approach and its potential to disrupt traditional drug discovery paradigms, paving the way for future commercialization efforts and market penetration.
See full Deepcure company page
